A PET study of effects of chronic 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) on serotonin markers in Göttingen minipig brain
暂无分享,去创建一个
Bente Pakkenberg | Steen Jakobsen | Paul Cumming | Luciano Minuzzi | B. Pakkenberg | L. Minuzzi | S. Jakobsen | P. Cumming | M. Andreasen | A. K. Stark | J. Gramsbergen | A. Olsen | Svend B Jensen | S. Jensen | Aage K Olsen | Anette K Stark | Mette Møller | Kjeld Benda | Jan Bert Gramsbergen | Mette F Andreasen | Mette Møller | Kjeld Benda | M. F. Andreasen
[1] M. Colado,et al. Studies on the role of dopamine in the degeneration of 5‐HT nerve endings in the brain of Dark Agouti rats following 3,4‐methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration , 1999, British journal of pharmacology.
[2] F. Turkheimer,et al. On the Undecidability among Kinetic Models: From Model Selection to Model Averaging , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[3] G. Ricaurte,et al. Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. , 1992, The Journal of pharmacology and experimental therapeutics.
[4] L. Reneman,et al. The Acute and Chronic Effects of MDMA (“Ecstasy”) on Cortical 5-HT2A Receptors in Rat and Human Brain , 2002, Neuropsychopharmacology.
[5] M. Jurima‐Romet,et al. Evidence for the catalysis of dextromethorphan O-demethylation by a CYP2D6-like enzyme in pig liver. , 2000, Toxicology in vitro : an international journal published in association with BIBRA.
[6] A. Gjedde,et al. MDMA‐evoked changes in cerebral blood flow in living porcine brain: Correlation with hyperthermia , 2004, Synapse.
[7] A. Gjedde,et al. Normalization of markers for dopamine innervation in striatum of MPTP‐lesioned miniature pigs with intrastriatal grafts , 2001, Acta neurologica Scandinavica.
[8] F. Wappler,et al. Induction of Malignant Hyperthermia in Susceptible Swine by 3,4-Methylenedioxymethamphetamine (“Ecstasy”) , 2003, Anesthesiology.
[9] M. Colado,et al. The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) , 2003, Pharmacological Reviews.
[10] R Myers,et al. Effect of 5‐HT on binding of [11C] WAY 100635 to 5‐HT1A receptors in rat brain, assessed using in vivo microdialysis and PET after fenfluramine , 2001, Synapse.
[11] J. Langston,et al. Nigrostriatal Reduction of Aromatic L‐Amino Acid Decarboxylase Activity in MPTP‐Treated Squirrel Monkeys: In Vivo and In Vitro Investigations , 2000, Journal of neurochemistry.
[12] R. de la Torre,et al. Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. , 2002, Journal of analytical toxicology.
[13] John F. Young,et al. Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. , 2003, Neurotoxicology.
[14] Flemming Andersen,et al. MR-Based Statistical Atlas of the Göttingen Minipig Brain , 2001, NeuroImage.
[15] G. Battaglia,et al. MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons , 1988, Pharmacology Biochemistry and Behavior.
[16] L. Seiden,et al. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. , 1996, The Journal of pharmacology and experimental therapeutics.
[17] H. Gundersen. Stereology of arbitrary particles * , 1986, Journal of microscopy.
[18] J. Fisk,et al. Verbal working memory deficits in current and previous users of MDMA , 2004, Human psychopharmacology.
[19] Jan Corfixen Sørensen,et al. The DaNeX Study of Embryonic Mesencephalic, Dopaminergic Tissue Grafted to a Minipig Model of Parkinson's Disease: Preliminary Findings of Effect of MPTP Poisoning on Striatal Dopaminergic Markers 1 , 2000, Cell transplantation.
[20] R. Glennon,et al. Identification of metabolites of 3,4-methylenedioxymethamphetamine in rats. , 1990, Drug and alcohol dependence.
[21] J. Robinson,et al. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? , 2001, Psychopharmacology.
[22] R. Foltz,et al. In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. , 1988, Chemical research in toxicology.
[23] G. Ricaurte,et al. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[24] H. J. G. Gundersen,et al. The new stereological tools: Disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[25] M. Casu,et al. Immunocytochemical study of the forebrain serotonergic innervation in Sardinian alcohol-preferring rats , 2004, Psychopharmacology.
[26] S. Kish. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? , 2002, Pharmacology Biochemistry and Behavior.
[27] Sung-Cheng Huang,et al. Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model , 2003, NeuroImage.
[28] M. Farré,et al. Pharmacology of MDMA in Humans , 2000, Annals of the New York Academy of Sciences.
[29] John Hilton,et al. Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions , 2002 .
[30] G. Ricaurte,et al. Behavioral and Neurochemical Consequences of Long-Term Intravenous Self-Administration of MDMA and Its Enantiomers by Rhesus Monkeys , 2004, Neuropsychopharmacology.
[31] C. Friis,et al. Is cytochrome P450 CYP2D activity present in pig liver? , 2002, Pharmacology & toxicology.
[32] J R Nyengaard,et al. Tissue shrinkage and unbiased stereological estimation of particle number and size * , 2001, Journal of microscopy.
[33] M. Wilson,et al. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine , 1989, Neuroscience.
[34] R. Croft,et al. Chronic MDMA (ecstasy) use, cognition and mood , 2004, Psychopharmacology.
[35] U. McCann,et al. Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study , 1999, Psychopharmacology.
[36] Ralph Buchert,et al. A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. , 2004, The American journal of psychiatry.
[37] H. Wikström,et al. Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635 , 1997, Brain Research.
[38] R. de la Torre,et al. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. , 2000, British journal of clinical pharmacology.
[39] E. Azmitia,et al. Cellular Localization of the 5-HT1A Receptor in Primate Brain Neurons and Glial Cells , 1996, Neuropsychopharmacology.
[40] H. Pakkenberg,et al. MPTP-induced Parkinsonism in minipigs: A behavioral, biochemical, and histological study. , 1999, Neurotoxicology and teratology.
[41] P. Cumming,et al. Pig brain stereotaxic standard space: Mapping of cerebral blood flow normative values and effect of MPTP-lesioning , 2005, Brain Research Bulletin.
[42] G. Battaglia,et al. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[43] M. Wilson,et al. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. , 1988, JAMA.
[44] André Luxen,et al. Effect of endogenous serotonin on the binding of the 5‐HT1A PET ligand 18F‐MPPF in the rat hippocampus: kinetic β measurements combined with microdialysis , 2002, Journal of neurochemistry.
[45] R. de la Torre,et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. , 2004, Therapeutic drug monitoring.
[46] Latifa Rbah,et al. Displacement of the PET ligand 18F‐MPPF by the electrically evoked serotonin release in the rat hippocampus , 2003, Synapse.
[47] R. de la Torre,et al. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. , 2004, Trends in pharmacological sciences.
[48] R. Buchert,et al. Specific neurotoxicity of chronic use of ecstasy. , 2002, Toxicology letters.
[49] A. García-Osta,et al. Differential Regulation by Methylenedioxymethamphetamine of 5‐Hydroxytryptamine1A Receptor Density and mRNA Expression in Rat Hippocampus, Frontal Cortex, and Brainstem: The Role of Corticosteroids , 1997, Journal of neurochemistry.
[50] T Suhara,et al. In vivo binding properties of [carbonyl‐11C]WAY‐100635: Effect of endogenous serotonin , 2001, Synapse.
[51] R. Buchert,et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective , 2006, Journal of psychopharmacology.
[52] Z. Szabo,et al. In vivo detection of short‐ and long‐term MDMA neurotoxicity—a positron emission tomography study in the living baboon brain , 1998, Synapse.
[53] Alan A. Wilson,et al. [11C]‐NS 4194 versus [11C]‐DASB for PET imaging of serotonin transporters in living porcine brain , 2003, Synapse.
[54] E. D. De Souza,et al. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. , 1987, The Journal of pharmacology and experimental therapeutics.
[55] Liesbeth Reneman,et al. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons , 2001, The Lancet.
[56] Steen Jakobsen,et al. Mapping the amphetamine-evoked dopamine release in the brain of the Göttingen minipig , 2005, Brain Research Bulletin.
[57] Steen Jakobsen,et al. Behavioral response to novelty correlates with dopamine receptor availability in striatum of Göttingen minipigs , 2005, Behavioural Brain Research.
[58] Zsolt Szabo,et al. Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [11C]McN5652 and [11C]DASB , 2005, Neuropsychopharmacology.
[59] U. McCann,et al. Pharmacokinetic Profile of Single and Repeated Oral Doses of MDMA in Squirrel Monkeys: Relationship to Lasting Effects on Brain Serotonin Neurons , 2006, Neuropsychopharmacology.
[60] A. R. Green,et al. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (‘Ecstasy’) to rats , 1994, Neuropharmacology.
[61] B. Yamamoto,et al. Ascorbic acid prevents 3,4‐methylenedioxymethamphetamine (MDMA)‐induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5‐HT , 2001, Synapse.
[62] Albert Gjedde,et al. MDMA‐evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain , 2004, Synapse.
[63] Victor W. Pike,et al. Remotely-controlled production of the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635, via 11C-carboxylation of an immobilized Grignard reagent , 1996 .
[64] V. Sánchez,et al. Effect of Repeated (‘Binge’) Dosing of MDMA to Rats Housed at Normal and High Temperature on Neurotoxicdamage to Cerebral 5-Ht and Dopamine Neurones , 2004, Journal of psychopharmacology.
[65] Arne Møller,et al. Quantitative [18F]Fluorodopa/PET and Histology of Fetal Mesencephalic Dopaminergic Grafts to the Striatum of MPTP-Poisoned Minipigs , 2002, Cell transplantation.